SCLC: is it time for novel therapies?
The search for effective therapeutic targets in small cell lung cancer (SCLC) continues and a number of options have been identified. In the meantime the results of CASPIAN… read more.
The search for effective therapeutic targets in small cell lung cancer (SCLC) continues and a number of options have been identified. In the meantime the results of CASPIAN… read more.
Oligorecurrent and oligoprogressive NSCLC represent a treatment challenge. A case example of synchronous oligometastatic disease provided the framework for expert discussion…….. Written by Christine Clark.
Advances in the use of immunotherapy in thoracic malignancies continued in 2019 with the publication of the results of a number of landmark trials. This has prompted some… read more.
Three expert clinicians, Dr Marina Garassino, Dr Sanjay Popat and Professor Tony Mok presented and discussed cases that illustrated important aspects of the management of ALK-positive NSCLC …… … read more.
The final analyses of two key trials – Checkmate 227, part 1 and FLAURA should help to position nivolumab + ipilimumab combination treatment and to reinforce osimertinib as… read more.
For the second time this year, LungCancer.Med headed to Barcelona for the Annual European Society for Medical Oncology (ESMO) meeting. Written by Christine Clark